The health care market is failing to support new antibiotics used to treat some of the world’s most dangerous, drug-resistant “superbugs,” according to a new analysis by University of Pittsburgh School of Medicine infectious disease scientists.
In a study published today in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology, investigators used nationwide prescription data to determine that the current annual U.S. sales of new antibiotics to treat carbapenem-resistant Enterobacteriaceae (CRE), one of the world’s most insidious drug-resistant bacteria, is about $101 million annually — significantly short of the $1 billion believed to be necessary to assure the financial viability of a new antibiotic. Even if new anti-CRE agents were used as widely as possible to treat CRE infections, the projected market size is only $289 million.
“New drugs against CRE address a major, previously unmet medical need and are critical to save lives. If the market can’t support them, then that is a chilling commentary on the future of antibiotic development,” said lead author Cornelius J. Clancy, M.D., associate professor of medicine and director of the mycology program and Extensively Drug Resistant Pathogen Laboratory in Pitt’s Division of Infectious Diseases. “Without antibiotics against increasingly resistant bacteria and fungi, much of modern medicine may become infeasible, including cancer chemotherapies, organ transplantation and high-risk abdominal surgeries.”
CRE infections are estimated to cause 1.5 to 4.5 million hospitalizations worldwide each year. The Centers for Disease Control and Prevention has classified CRE as urgent threat pathogens and calls them the “nightmare bacteria.” The World Health Organization and Infectious Disease Society of America have designated CRE as highest priority pathogens for development of new antibiotics.
Since 2015, five antibiotics against CRE have gained U.S. Food and Drug Administration approval and trials have so far shown three of them to be more effective and less toxic than the previous first-line antibiotics. One of the developers of the new anti-CRE drugs — the biopharmaceutical company Achaogen — declared bankruptcy in April because of its steep losses.
After reporting earlier this year that new CRE antibiotics are being prescribed in only about a quarter of infections that warrant them, Clancy and senior author M. Hong Nguyen, M.D., Pitt professor of medicine and director of UPMC’s Antimicrobial Management Program, investigated the market needed to make antibiotic development sustainable. They found a shortfall in revenue potential, evidenced by the financial difficulties faced by drug companies that created the new anti-CRE drugs.
“The prudent approach when fighting bacteria is to have multiple treatment options in the pipeline so that when resistance is inevitably developed to the current drug, a new antibiotic is waiting in the wings,” said Nguyen. “But we found that market prospects will become even more daunting if more anti-CRE drugs are approved, which is bad news for infectious disease physicians and, more importantly, our patients.”
Clancy and Nguyen propose a combination of “push” and “pull” incentives to encourage sustainable antibiotic development, starting with approval of the bilateral DISARM Act, which currently is under consideration in Congress. DISARM would assure full Centers for Medicare and Medicaid Services reimbursement for use of new antibiotics against resistant infections in hospitalized patients, rather than subsuming antibiotic costs into the discounted bundled payment hospitals receive. This would remove the disincentive hospitals face in using more effective but more expensive new agents rather than cheaper, older agents.
There also needs to be a cultural and behavioral change among hospitals and clinicians to encourage faster adoption and appropriate use of new antibiotics, the researchers said. Infectious disease physicians and pharmacists need to take responsibility for educating the wider clinical community about the importance of quickly updating and following guidelines on the best possible antibiotics to be using for their patients.
The Latest on: The future of antibiotics
via Google News
The Latest on: The future of antibiotics
- Research shows benefits/risks of treating appendicitis with antibiotics instead of surgeryon October 5, 2020 at 1:05 pm
NEJM: Results of a first-of-its-kind clinical trial shed light on when antibiotics instead of surgery might be the better choice for treating appendicitis in some patients, according to researchers ...
- ABC transporters: A novel approach to the development of antibiotics, immunotherapy medications and anti-cancer drugson October 1, 2020 at 11:54 pm
A novel approach to ... Antibiotics as well as important drugs for the treatment of cancer and immune diseases are produced by microorganisms through multi-modular enzyme complexes called ...
- Scientists Sequence Genome of Mold That Gave Us Penicillin, the First Antibioticon September 24, 2020 at 9:51 am
The discovery of antibiotics is one of humanity's greatest achievements, and now a research team has revived the Penicillin mold to sequence its genome for the first time.
- How COVID-19 is accelerating the threat of antimicrobial resistanceon September 23, 2020 at 3:50 am
many highlighted that it was important not to overreact with antibiotic prescribing during COVID-19 and to continue following good stewardship practices to prevent larger problems in the future. A ...
- ENG’s Muhammad Zaman on the Growing Dangers of Antibiotic Resistanceon September 22, 2020 at 7:52 am
Whereas we have clear evidence that antibiotic resistance requires a collective approach ... but you also express a sense of optimism about the future. Where do you see reason for hope in addressing ...
- Lobby warns of health crisis, says resistance to antibiotics risingon September 21, 2020 at 12:08 pm
“Superbugs make antibiotics less effective in treating ... toll from superbugs during the current pandemic and into the future,” he said. Yamo spoke on Monday during the launch of a report ...
- The world is running out of antibiotics, WHO report confirmson September 15, 2020 at 12:10 pm
WHO works with countries and partners to improve infection prevention and control and to foster appropriate use of existing and future antibiotics. WHO is also developing guidance for the ...
- Only 34 countries with plans to fight threat of antibiotic resistance, says WHOon September 14, 2020 at 6:43 pm
Antimicrobial drugs such as antibiotics and anti-virals are used ... resistant infections as “one of the biggest threats to the future of global health”. “Yet in most areas of the world ...
- Animal Antibiotics And Antimicrobials Market : Future On Recent Innovation 2026 | Zoetis, Boehringer Ingelheim International GmbH, Merck & Co.on September 12, 2020 at 7:08 am
historical and future data by types, applications and regions. Chapter 1: Animal Antibiotics And Antimicrobials Overview, Product Overview, Market Segmentation, Market Overview of Regions ...
- Breast Milk Microbiota in Mothers of Preterm Infants Affected by Antibioticson September 8, 2020 at 5:05 am
She added that advances in technology may allow for quicker diagnoses of infection and better antibiotic stewardship in the future. As for the rapidly moving field of microbiome research ...
via Bing News